PARP1 and breast cancer: We observed an analogous decrease in RPA2 hyperphosphorylation in MDA-MB231 breast cancer cells transiently depleted in PARG by siRNA and treated with 2 mM HU for 24 h, and this hyperphosphorylation was restored in the presence of a PARP inhibitor (data not shown).